

Kyowa Hakko Kirin Co., Ltd.

Consolidated Financial Summary Fiscal 2014 Interim

(January 1, 2014 – June 30, 2014)

This document is an English translation of parts of the Japanese-language original. All financial information has been prepared in accordance with generally accepted accounting principles in Japan. It contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. Actual financial results may differ materially depending on a number of factors, including fluctuations in exchange rates, changing economic conditions, legislative and regulatory developments, delays in new product launches, and pricing and product initiatives of competitors.

Summary of Financial Statements for the Interim Period of the Year Ending December 31, 2014

Kyowa Hakko Kirin Co., Ltd.

July 30, 2014

Stock Code: 4151	Listed exchanges: 1st Section of the Tokyo Stock Exchange
URL: http://www.kyowa-kirin.com	Inquiries: Shigeru Morotomi, Executive Officer
President: Nobuo Hanai	Corporate Communications Department
	Telephone: 81-3-3282-0009
Scheduled date of submission of Financial Report: August 7, 2014	Scheduled start date of dividend payment: September 1, 2014

Appendix materials prepared to accompany the quarterly financial report: Yes

Quarterly results presentation meeting: Yes

(For institutional investors and securities analysts)

1. Consolidated Financial Results for the six months ended June 30, 2014

(% changes are compared to the same period of the previous fiscal year)

(1) Consolidated business performance

(Millions of yen, rounded down)

	Six months to June 30, 2014	Change (%)	Six months to June 30, 2013	Change (%)
Net sales	161,899	(4.6)	169,707	2.1
Operating income	18,411	(32.3)	27,176	6.2
Ordinary income	16,865	(36.4)	26,523	14.8
Net income	9,185	(48.0)	17,678	53.4
Net income per share (¥)	16.78		32.29	
Fully diluted net income per share (¥)	16.77		32.27	

Note: Comprehensive income: Six months to June, 2014: ¥6,682 million (-76.9%); Six months to June, 2013: ¥28,944 million (+116.7%)

(2) Consolidated financial position

(Millions of yen, rounded down)

	As of June 30, 2014	As of December 31, 2013
Total assets	683,131	719,257
Net assets	594,321	595,415
Shareholders' equity ratio (%)	87.0	82.6

Note: Total shareholders' equity: June 30, 2014: ¥594,020 million; December 31, 2013: ¥593,957 million

2. Dividends

Dividends per share	Fiscal year ending December 31, 2014 (forecast)	Fiscal period ended December 31, 2013
First quarter per share (¥)	---	---
Interim dividend per share (¥)	12.50	12.50
Third quarter dividend per share (¥)	---	---
Year-end dividend per share (¥)	12.50 (forecast)	12.50
Total dividend per share (¥)	25.00 (forecast)	25.00

Note: Changes to the dividend forecast during the term: None.

3. Consolidated results forecasts for the fiscal year ending December 31, 2014

(Millions of yen)

	January 1, 2014 to December 31, 2014	Change (%)
Net sales	337,000	(1.1)
Operating income	45,000	(13.1)
Ordinary income	37,000	(25.3)
Net income	20,000	(33.5)
Net income per share (¥)	36.54	

Notes: Changes to the consolidated results forecast during the term: Yes

Notes:

- 1) **Transfer of important subsidiaries during the period (transfers of specified subsidiaries resulting in changes in the scope of consolidation during the period under review):** No
- 2) **Use of special accounting procedures in the preparation of quarterly consolidated financial statements:** Yes
See Page 7, Section 2. Summary information (Other items)
- 3) **Changes to accounting policies, accounting estimates, and restatement of revisions:**
 1. Changes following revisions to accounting standards: No
 2. Changes to accounting policies other than 1. above: No
 3. Changes to accounting estimates: No
 4. Restatement of revisions: No

4) Number of shares outstanding (ordinary shares)

1. Number of shares outstanding (including treasury shares)	June 30, 2014	576,483,555 shares	December 31, 2013	576,483,555 shares
2. Number of treasury shares	June 30, 2014	29,126,720 shares	December 31, 2013	29,143,513 shares
3. Average number of shares during the six-month period	Quarter ended June 30, 2014	547,354,064 shares	Quarter ended June 30, 2013	547,412,193 shares

Notice regarding quarterly review procedures

The Financial Products Law review process for this quarterly financial report was not yet complete at the time this financial report was issued.

Notice regarding the appropriate use of the financial forecasts and other special comments

1. There is a change to the forecasts for the fiscal year ending December 31, 2014 announced on January 31, 2014.
2. Forecasts of results and other forward-looking statements contained in this document are based on information available to and on assumptions deemed reasonable by the company at the time of release of this document. Actual results may be affected by a range of factors and may differ materially.

Contents

1. Operating Results and Financial Statements

(1) Summary of consolidated business performance.....	4
(2) Summary of consolidated financial position.....	6
(3) Consolidated results forecasts.....	6

2. Summary Information (Other items)

(1) Changes to significant subsidiaries during the period.....	7
(2) Use of special accounting procedures in the preparation of this report.....	7
(3) Changes to accounting policies, accounting estimates, and restatement of revisions.....	7

3. Consolidated financial statements

(1) Consolidated balance sheets.....	8
(2) Consolidated statements of income and comprehensive income	
Consolidated statements of income.....	10
Consolidated Statements of comprehensive income.....	11
(3) Consolidated Statements of Cash Flows.....	12
(4) Notes to the consolidated financial statements.....	14
(Items related to going concern assumption).....	14
(Notes on significant change in shareholders' equity).....	14
(Segment information).....	14
(Material post-balance sheet events)	15

1. Operating Results and Financial Statements

(1) Summary of business performance

Net sales for the first half of the fiscal year (January 1, 2014 to June 30, 2014) were ¥161.8 billion (down 4.6% compared to the first half of the previous fiscal year), operating income was ¥18.4 billion (down 32.3%) and ordinary income was ¥16.8 billion (down 36.4%). Net income for the half year was ¥9.1 billion (down 48.0%).

- Net sales and operating income decreased due to the impact of the drug price revision in April and a decline in licensing revenue
- The decline in ordinary income was a result of the decrease in operating income, the booking of foreign exchange losses and other factors while the decline in net income was due to recording gain on sales of subsidiaries and affiliates' stocks and other factors in the previous fiscal year.

Performance by segment

Pharmaceuticals business

1. Results

In the Pharmaceuticals business, net sales were ¥119.5 billion (down 8.0%) and operating income was ¥14.1 billion (down 41.2%).

- Domestic sales of ethical pharmaceutical products declined compared to the same period of the previous fiscal year, impacted by the drug price revision in April and other factors.
 - Sales of core product NESP[®], a treatment for renal anemia, were steady and sales increased over the same period in the previous fiscal year, in which sales declined due to lower shipments following the launch of a unified dosage product in December 2012. Sales of ALLELOCK[®], an anti-allergy agent, and Patanol[®] anti-allergy eye drops declined year on year due to the effects of lower amounts of airborne pollen. Sales of ALLELOCK[®] were also impacted by the drug price revision and the market penetration of generics.
 - Sales of NOURIAST[®], an antiparkinsonian agent, REGPARA[®], a treatment for secondary hyperparathyroidism during dialysis therapy, Abstral[®], a treatment for cancer pain, ASACOL[®], an ulcerative colitis treatment, Fentos[®], a transdermal analgesic for persistent pain, and other products advanced steadily.
- In the licensing-out of technologies and export of pharmaceutical products, exports were steady but sales declined due to a decline in licensing revenue.
- ProStrakan net sales were ¥13.3 billion (up 24.0%), operating income (after amortization of goodwill, etc.) was ¥0.6 billion (compared to an operating loss of ¥0.3 billion in the same period in the previous fiscal year). Sales of Abstral[®] a treatment for cancer pain, and other core products, grew strongly.

2. Research and development

Nephrology

(Domestic)

- In March we applied for approval for calcium receptor agonist REGPARA[®] 12.5mg.

(Overseas)

- In China, we received approval in June of Cinacalcet Hydrochloride (product name in Japan: REGPARA[®]), a calcium receptor agonist.

Oncology

(Domestic)

- In February we received approval for additional indications of hypercalcemia in patients with parathyroid carcinoma, and hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy or who experience recurrent primary hyperparathyroidism following surgery, and for dosage and administration for REGPARA[®].
- In March we received approval for additional indications for relapsed or refractory CCR4-positive peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) and for dosage and administration for anti-CCR4 humanized antibody POTELIGEO[®].
- In March we applied for approval for additional indication of NESP[®], a treatment for renal anemia, for anemia with myelodysplastic syndrome.
- In February, we temporarily withdrew our application for approval for additional indication for untreated CCR4-positive adult T-cell leukemia-lymphoma (ATL) for POTELIGEO[®]. We re-filed the application in June.
- We are currently seeking approval for sustained-duration G-CSF product KRN125 for the treatment of chemotherapy induced febrile neutropenia (application filed in June 2013).
- In February, we initiated a phase III clinical study evaluating ARQ 197 patients with c-Met diagnostic-high inoperable hepatocellular carcinoma treated with one prior sorafenib therapy.
- In April we added Japan as a site for an ongoing phase III clinical trial in the United States and Europe to evaluate the efficacy and safety of KW-0761 (product name in Japan: POTELIGEO[®]), targeting relapsed or refractory cutaneous T-Cell Lymphoma.

Immunology and allergy

(Domestic)

- In April, we began conducting trials of anti-IL-5 receptor humanized antibody KHK4563 in Japan and South Korea, targeting asthma patients, as part of the global phase III trials being conducted by our licensing partner, AstraZeneca.

CNS

(Domestic)

- In January, we received approval for a new formulation (granules) for anti-epileptic drug TOPINA[®].

Bio-Chemicals business

In the Bio-Chemicals business, net sales were ¥44.0 billion (up 6.9%) and operating income was ¥4.2 billion (up 36.0%).

Domestic business

- Sales in the pharmaceutical and medical treatment fields increased compared to the first half of the previous fiscal year.
 - In the pharmaceutical and medical treatment fields, sales of active pharmaceutical ingredients (APIs) for generic pharmaceuticals grew.
- In the healthcare field, year-on-year mail-order sales, such as those of Ornithine, increased but sales of food and beverage raw materials declined slightly.

Overseas business

- Sales from overseas businesses were higher than the previous year due in part to a weaker yen.
 - In the U.S., sales were broadly unchanged from the same period in the previous year despite intensifying

competition in some amino acids for supplements.

- In Europe, sales volumes of some products, such as infusion-use amino acids, declined due to the impact of customer production schedules, but sales increased overall due in part to yen depreciation.
- In Asia, sales increased significantly due in part to early shipments of some nucleic acids and related compounds to the China market and a weaker yen.

(2) Summary of consolidated financial position

- Total assets as of June 30, 2014 were ¥683.1 billion, a decrease of ¥36.1 billion compared to the end of the previous fiscal year.
 - Current assets decreased by ¥33.2 billion to ¥296.0 billion due to a decrease in notes and accounts receivable-trade and short-term loans receivable to the parent company and other factors, and despite an increase in inventories.
 - Non-current assets decreased by ¥2.8 billion to ¥387.0 billion due to a decrease in goodwill, marketing rights and other intangible assets as a result of amortization, and despite an increase in property, plant and equipment and other factors.
- Liabilities were ¥88.8 billion; a decrease of ¥35.0 billion compared to the end of the previous fiscal year, due to declines in notes and accounts payable-trade and accounts payable-other, and other factors, as well as a significant decrease in provision for retirement benefits due to a cash payment of ¥19.0 billion to retirement benefit trusts.
- Net assets were ¥594.3 billion, a decrease of ¥1.0 billion from the end of the previous fiscal year due to dividend payments, a decline in the foreign currency translation adjustment, and other factors, and despite the addition of net income for the period.

As a result, the shareholders' equity ratio as of the end of the second quarter was 87.0%, an increase of 4.4 percentage points compared to the end of the previous fiscal year.

Cash flow summary

- Cash and cash equivalents at the end of the interim period were ¥11.4 billion, a decrease of ¥7.8 billion compared to ¥19.2 billion at the end of the previous fiscal period. Short-term loans receivable to the parent company exceeding three months, which are not included in cash and cash equivalents, were ¥89.5 billion, a decrease of ¥20.5 billion compared to ¥110.0 billion at the end of the previous fiscal period. These loans were made as a part of our asset resource management.

The main cash flows and factors affecting them during the interim period were as follows:
- Net cash used in operating activities was ¥0.5 billion (compared to a net inflow of ¥20.6 billion in the same period of the previous fiscal year). The primary factors affecting cash inflows were net income before income taxes of ¥16.7 billion, depreciation expenses of ¥10.8 billion, and amortization of goodwill of ¥6.0 billion. The main cash outflows included the retirement benefit trust contribution of ¥19.0 billion and income taxes paid of ¥11.6 billion.
- Net cash provided by investing activities was ¥1.6 billion (compared to a net outflow of ¥34.2 billion in the same period of the previous fiscal year). The primary factors affecting cash outflow was ¥16.3 billion for the purchase of property, plant and equipment. The major cash inflows included a net decrease in short-term loans receivable of ¥20.4 billion.
- Net cash used in financing activities was ¥7.8 billion (a 48.3% increase compared to the same period of the previous fiscal year). The main outflow was ¥6.8 billion for cash dividends paid.

(3) Consolidated results forecasts

Consolidated results for the first half of fiscal year 2014 were higher than initial expectations due to the smaller than anticipated impact of the drug price revision on the Pharmaceuticals business as well as the

curtailment of SG&A expenses and their deferment to the second half of the fiscal year. In light of these factors we have revised our full-year consolidated earnings forecast.

In addition, the estimated effect on the consolidated results of the July 11, 2014 announcement—"ProStrakan enters into agreement to buy Archimedes"—is currently being assessed and has not been factored into the earnings forecast.

Revision to consolidated full-year forecast announced January 31, 2014

	Net Sales	Operating Income	Ordinary income	Net income	Net income per share
	Million yen	Million yen	Million yen	Million yen	Yen
Previous Forecast (A)	337,000	41,000	35,000	20,000	36.54
Revised forecast (B)	337,000	45,000	37,000	20,000	36.54
Change (B-A)	—	4,000	2,000	—	—
Rate of change (%)	—	9.8	5.7	—	—
Fiscal 2013 results	340,611	51,773	49,502	30,078	54.95

2. Summary Information (Other items)

(1) Changes to significant subsidiaries during the period

No applicable items.

(2) Use of special accounting procedures in the preparation of this report

Calculations for tax expenses use an estimated effective tax rate for income before income taxes based on reasonable assumptions of an effective tax rate after the application of tax effect accounting for net income before income taxes for the consolidated fiscal year, including income before income taxes of the six-month period under review.

(3) Changes to accounting policies, accounting estimates, and restatement of revisions

No applicable items.

3. Consolidated financial statements

(1) Consolidated Balance Sheets

	<i>Millions of yen</i>	
	As of June 30, 2014	As of December 31, 2013
ASSETS		
Current assets:		
Cash and deposits	15,557	20,190
Notes and accounts receivable - trade	93,422	98,602
Merchandise and finished goods	56,021	50,863
Work in process	14,299	13,465
Raw materials and supplies	9,586	11,371
Deferred tax assets	10,378	10,409
Short-term loans receivable	89,661	113,133
Other	7,559	11,780
Allowance for doubtful accounts	(420)	(497)
Total current assets	296,066	329,320
Noncurrent assets:		
Property, plant and equipment		
Buildings and structures	130,860	132,861
Accumulated depreciation	(88,778)	(90,637)
Buildings and structures, net	42,082	42,223
Machinery, equipment and vehicles	149,825	146,935
Accumulated depreciation	(128,224)	(125,860)
Machinery, equipment and vehicles, net	21,600	21,075
Land	54,449	54,620
Construction in progress	17,313	13,501
Other	48,404	47,795
Accumulated depreciation	(41,618)	(41,297)
Other, net	6,785	6,498
Total property, plant and equipment	142,232	137,919
Intangible assets		
Goodwill	158,843	163,713
Marketing rights	42,820	46,519
Other	1,403	1,841
Total intangible assets	203,067	212,073
Investments and other assets		
Investment securities	23,123	24,602
Deferred tax assets	3,968	3,893
Other	14,869	11,638
Allowance for doubtful accounts	(196)	(191)
Total investments and other assets	41,765	39,942
Total non-current assets	387,065	389,936
Total assets:	683,131	719,257

Consolidated Balance Sheets (continued)

Millions of yen

	As of June 30, 2014	As of December 31, 2013
LIABILITIES		
Current liabilities:		
Notes and accounts payable - trade	17,582	22,589
Short-term loans payable	5,763	6,207
Accounts payable - other	28,370	36,519
Income taxes payable	7,266	10,483
Provision for sales rebates	990	1,217
Provision for point card certificates	289	254
Provision for bonuses	273	342
Other	6,666	7,462
Total current liabilities	67,202	85,076
Noncurrent liabilities:		
Deferred tax liabilities	11,349	11,807
Provision for retirement benefits	2,728	19,196
Provision for directors' retirement benefits	130	134
Provision for environmental measures	104	266
Allowance for loss on plants reorganization	3,390	3,390
Asset retirement obligations	346	374
Other	3,558	3,597
Total noncurrent liabilities	21,607	38,765
Total liabilities:	88,809	123,841
NET ASSETS		
Shareholders' equity:		
Capital stock	26,745	26,745
Capital surplus	512,326	512,328
Retained earnings	68,232	65,888
Treasury stock	(26,628)	(26,632)
Total shareholders' equity	580,676	578,329
Other accumulated comprehensive income adjustments		
Valuation difference on available-for-sale securities	1,473	1,414
Foreign currency translation adjustment	11,871	14,214
Total other accumulated comprehensive income adjustments	13,344	15,628
Subscription rights to shares:	301	306
Minority interests:	--	1,150
Total net assets:	594,321	595,415
Total liabilities and net assets:	683,131	719,257

(2) Consolidated Statements of Income

Millions of yen

	January 1, 2014 to June 30, 2014	January 1, 2013 to June 30, 2013
Net sales	161,899	169,707
Cost of sales	63,685	64,547
Gross profit	98,213	105,159
Selling, general and administrative expenses		
Research and development expenses	21,896	20,988
Amortization of goodwill	6,096	5,749
Other	51,809	51,244
Total selling, general and administrative expenses	79,802	77,982
Operating income	18,411	27,176
Non-operating income		
Interest income	364	375
Dividend income	262	529
Foreign exchange gains	--	433
Gain on valuation of derivatives	629	668
Other	350	396
Total non-operating income	1,605	2,402
Non-operating expenses		
Interest expenses	119	144
Foreign exchange losses	1,051	--
Equities in losses in affiliates	1,120	2,075
Loss on disposal of noncurrent assets	386	217
Other	472	618
Total non-operating expenses	3,151	3,055
Ordinary income	16,865	26,523
Extraordinary income		
Insurance Income	308	--
Gain on sales of subsidiaries and affiliates' stocks	--	2,758
Gain on sales of investment securities	--	1,033
Gain on sales of noncurrent assets	--	662
Total extraordinary income	308	4,455
Extraordinary loss		
Loss on sales of stocks of subsidiaries and affiliates	233	--
Loss due to fire	188	--
Loss on valuation of shares in affiliate companies	--	121
Total extraordinary loss	421	121
Income before income taxes and minority interests	16,752	30,856
Income taxes	7,566	13,134
Income before minority interests	9,185	17,722
Minority interests in income	--	44
Net income	9,185	17,678

Consolidated Statements of Comprehensive Income

Millions of yen

	January 1, 2014 to June 30, 2014	January 1, 2013 to June 30, 2013
Income before minority interests	9,185	17,722
Other comprehensive income		
Valuation difference on available-for-sale securities	58	3,259
Foreign currency translation adjustment	(2,562)	7,963
Total other comprehensive income	(2,503)	11,222
Comprehensive income	6,682	28,944
(Comprehensive attributable to)		
Comprehensive income attributable to owners of the parent	6,682	28,754
Comprehensive income attributable to minority interests	--	190

(3) Consolidated Statements of Cash Flows

	<i>Millions of Yen</i>	
	January 1, 2014 to June 30, 2014	January 1, 2013 to June 30, 2013
Net cash provided by (used in) operating activities		
Income before income taxes and minority interests	16,752	30,856
Depreciation and amortization	10,822	9,984
Amortization of goodwill	6,096	5,749
Increase (decrease) in provision for retirement benefits	(33)	(331)
Decrease (increase) in prepaid pension costs	(773)	(558)
Contribution to retirement benefit trust	(19,000)	--
Interest and dividend income	(626)	(904)
Interest expenses	119	144
Equity in (earnings) losses of affiliates	1,120	2,075
Loss (gain) on sale and retirement of property, plant and	142	(937)
Loss (gain) on sale of investment securities	(7)	(662)
Loss (gain) on sale of stocks of subsidiaries and affiliates	233	(2,755)
Decrease (increase) in notes and accounts	4,702	4,552
Decrease (increase) in inventories	(4,937)	(5,671)
Increase (decrease) in notes and accounts payable-trade	(4,438)	(4,398)
Other, net	382	(708)
Subtotal	10,553	36,434
Interest and dividend income received	773	1,024
Interest expenses paid	(234)	(188)
Income taxes paid	(11,640)	(16,594)
Net cash provided by (used in) operating activities	(548)	20,675

Consolidated Statements of Cash Flows (continued)

	<i>Millions of Yen</i>	
	January 1, 2014 to June 30, 2014	January 1, 2013 to June 30, 2013
Net cash provided by (used in) investing activities		
Purchase of property, plant and equipment	(16,306)	(10,794)
Proceeds from sale of property, plant and equipment	100	1,651
Purchase of intangible assets	(1,966)	(12,755)
Purchase of investment securities	(1,150)	(1,950)
Proceeds from sale of investment securities	55	3,766
Proceeds from sale of stocks of subsidiaries and affiliates	1,000	3,247
Payments into time deposits	(1,136)	(3,687)
Proceeds from withdrawal of time deposits	1,067	2,965
Net decrease (increase) in short-term loans	20,453	(15,999)
Other, net	(470)	(660)
Net cash provided by (used in) investing activities	1,645	(34,218)
Net cash provided by (used in) financing activities		
Net increase (decrease) in short-term loans payable	(893)	307
Cash used to purchase own shares	(55)	(66)
Cash dividends paid	(6,841)	(5,475)
Other, net	(83)	(75)
Net cash provided by (used in) financing activities	(7,873)	(5,309)
Effect of exchange rate change on cash and cash equivalents	(1,042)	1,031
Net increase (decrease) in cash and cash equivalents	(7,818)	(17,821)
Cash and cash equivalents at beginning of period	19,242	50,334
Cash and cash equivalents at end of period	11,424	32,512

(4) Notes to the consolidated financial statements

(Items related to going concern assumption)

No applicable items

(Notes on significant change in shareholders' equity)

No applicable items

(Segment information)

1. Sales and profit (loss) by segment

Fiscal 2014 segment information by business type (January 1, 2014 – June 30, 2014)

(Millions of yen)

	Pharmaceuticals	Bio-Chemicals	Total	Adjustments	Consolidated
Net sales					
Sales to external customers	118,957	42,941	161,899	--	161,899
Inter-segment sales and transfers	580	1,112	1,693	(1,693)	--
Total sales	119,537	44,054	163,592	(1,693)	161,899
Segment income	14,179	4,221	18,401	10	18,411

Notes: 1. The ¥10 million for adjustments of segment income is due to intersegment eliminations.
2. In segment income, operating income from the Consolidated Statements of Income has been adjusted.

2. Sales and profit (loss) by segment

Fiscal 2013 segment information by business type (January 1, 2013 – June 30, 2013)

(Millions of yen)

	Pharmaceuticals	Bio-Chemicals	Total	Adjustments	Consolidated
Net sales					
Sales to external customers	129,206	40,501	169,707	--	169,707
Inter-segment sales and transfers	743	706	1,450	(1,450)	--
Total sales	129,950	41,207	171,157	(1,450)	169,707
Segment income	24,125	3,103	27,228	(51)	27,176

Notes: 1. The minus ¥51 million for adjustments of segment income is due to intersegment eliminations.
2. In segment income, operating income from the Consolidated Statements of Income has been adjusted.

(Material post-balance sheet events)

Agreement by ProStrakan to acquire Archimedes

On July 11, 2014 Kyowa Hakko Kirin subsidiary, Prostrakan Group plc (“Prostrakan”), agreed to acquire Archimedes Pharma Limited (“Archimedes”) from investment company Novo A/S, which is managed by Novo Nordisk Foundation.

1.Objective of acquisition

Archimedes is a European specialty pharmaceutical company that provides ethical pharmaceutical products in the pain, cancer and critical care fields. Archimedes’ core product PecFent is already used as Fentanyl nasal spray for pain management to alleviate intense pain in cancer patients undergoing opioid therapy. This product uses a drug delivery system developed in-house by Archimedes that is protected by multiple patents.

This acquisition represents a major step forward in the pursuit of Kyowa Hakko Kirin’s medium-term plan vision of becoming a global specialty pharmaceutical group and we are confident that it will also provide many strategic benefits to ProStrakan.

2.Outline of acquisition

On completion of this acquisition Archimedes will become a 100%-owned subsidiary of ProStrakan. Please note that closing of the transaction is subject to anti-trust approvals in Germany (expected in August 2014).

The total expected acquisition amount of GBP 230 million includes the equity acquisition amount and also repayment of interest-bearing debt of the target company. Kyowa Hakko Kirin plans to use its cash on hand to consummate the acquisition.

3.Outline of Archimedes Pharma

(1) Name: Archimedes Pharma Limited

(2) Business: Development and sale of ethical pharmaceuticals

(3) Location: Reading, Berkshire, U.K.

(4) Capital: GBP 543,000 (as of end December 2013)

(5) Shares: Not listed

(6) Consolidated sales: GBP 41 million (fiscal year to December 2013)